The GARDASIL vaccine can prevent cervical carcinoma caused by human papilloma virus (HPV) (results from our participation and from the study carried out in Greece).
GARDASIL is a quadrivalent recombinant vaccine against the human papilloma virus (HPV), more specifically against types 6, 11, 16 and 18. We present our 10 cases of vaccinated patients, aged from 16 to 23, whose condition was followed for a period of 5 years after vaccination. Our study was part of the world program for investigating GARDASIL, which included 25,000 patients from 33 countries. The results showed that GARDASIL vaccination reduced precancerous cervical, vaginal and vulvar lesions, associated with HPV types 16 and 18, as well as condylomas associated with HPV types 6 and 11.
Ansstasiou-Fotaki
P
P
Deligeoroglou
E
E
Kreatsas
G
G
D000293:Adolescent; D000328:Adult; D052685:Alphapapillomavirus / Q000276:immunology*; D000914:Antibodies, Viral / Q000032:analysis; D004334:Drug Administration Schedule; D005260:Female; D006115:Greece; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control*
D000914:Antibodies, Viral; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines